The Impact of Steatosis on Chronic Hepatitis C Progression and Response to Antiviral Treatments
2021
Phumelele Yvonne Siphepho | Yi-Ting Liu | Ciniso Sylvester Shabangu | Jee-Fu Huang | Chung-Feng Huang | Ming-Lun Yeh | Ming-Lung Yu | Shu-Chi Wang
Metabolic derangement is characteristic in patients with hepatitis C virus (HCV) infection. Aside from established liver injury, various extrahepatic metabolic disorders impact the natural history of the disease, clinical outcomes, and the efficacy of antiviral therapy. The presence of steatosis, recently redefined as metabolic-associated fatty liver disease (MAFLD), is a common feature in HCV-infected patients, induced by host and/or viral factors. Most chronic HCV-infected (CHC) patients have mild steatosis within the periportal region of the liver with an estimated prevalence of 40% to 86%. Indeed, this is higher than the 19% to 50% prevalence observed in patients with other chronic liver diseases such as chronic hepatitis B (CHB). The histological manifestations of HCV infection are frequently observed in genotype 3 (G-3), where relative to other genotypes, the prevalence and severity of steatosis is also increased. Steatosis may independently influence the treatment efficacy of either interferon-based or interferon-free antiviral regimens. This review aimed to provide updated evidence of the prevalence and risk factors behind HCV-associated steatosis, as well as explore the impact of steatosis on HCV-related outcomes.
Show more [+] Less [-]Bibliographic information
This bibliographic record has been provided by Directory of Open Access Journals